{"id":"etoposide-cisplatin-combined-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL1200645","moleculeType":"Small molecule","molecularWeight":"668.54"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etoposide is a topoisomerase II inhibitor that prevents DNA repair and causes double-strand breaks, while cisplatin is a platinum-based alkylating agent that cross-links DNA strands and prevents replication. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells. This combination is particularly effective against small cell lung cancer and other solid tumors.","oneSentence":"Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:44.675Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Other solid tumors (specific indications in Phase 3 trial unknown)"}]},"trialDetails":[{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT05019716","phase":"PHASE1, PHASE2","title":"Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-13","conditions":"Advanced NUT Carcinoma, Metastatic NUT Carcinoma, Unresectable NUT Carcinoma","enrollment":36},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06157827","phase":"PHASE1, PHASE2","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"Nanjing Leads Biolabs Co.,Ltd","startDate":"2023-12-08","conditions":"Advanced Neuroendocrine Carcinoma","enrollment":178},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT04602533","phase":"PHASE2","title":"Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Hopp","startDate":"2020-12-21","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":105},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT07425795","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-10","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":36},{"nctId":"NCT05403723","phase":"PHASE1","title":"Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC","status":"SUSPENDED","sponsor":"University of Maryland, Baltimore","startDate":"2026-06-30","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":50},{"nctId":"NCT07149363","phase":"PHASE2","title":"Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2026-02","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":65},{"nctId":"NCT06712355","phase":"PHASE3","title":"Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-02-03","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":621},{"nctId":"NCT02875314","phase":"PHASE4","title":"HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Parth Patel","startDate":"2015-09","conditions":"Medulloblastoma, Central Nervous System Embryonal Tumors","enrollment":250},{"nctId":"NCT06943235","phase":"PHASE2","title":"Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-25","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT07381543","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-03","conditions":"Localized Small Cell Lung Cancer","enrollment":76},{"nctId":"NCT07381829","phase":"PHASE1","title":"A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer","status":"RECRUITING","sponsor":"HC Biopharma Inc.","startDate":"2025-10-27","conditions":"Advanced Solid Tumor Cancer","enrollment":328},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT00336024","phase":"PHASE3","title":"Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-22","conditions":"Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified","enrollment":91},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT07349225","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Dalian Medical University","startDate":"2026-01-31","conditions":"ES-SCLC","enrollment":46},{"nctId":"NCT05353257","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-05-17","conditions":"Limited-Stage Small Cell Lung Cancer","enrollment":511},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT03643133","phase":"PHASE2","title":"Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2018-10-23","conditions":"Osteosarcoma","enrollment":60},{"nctId":"NCT03533582","phase":"PHASE3","title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-24","conditions":"Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma","enrollment":537},{"nctId":"NCT06132113","phase":"PHASE1","title":"DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-01-22","conditions":"Neuroendocrine Neoplasms","enrollment":55},{"nctId":"NCT04745689","phase":"PHASE2","title":"Study of AZD2811 + Durvalumab in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-02-23","conditions":"Small-Cell Lung Cancer","enrollment":31},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT05664971","phase":"PHASE1, PHASE2","title":"JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2023-02-09","conditions":"Advanced Lung Cancer","enrollment":119},{"nctId":"NCT04602377","phase":"PHASE2","title":"Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2021-08-04","conditions":"Small Cell Ovarian Carcinoma","enrollment":27},{"nctId":"NCT03582475","phase":"PHASE1","title":"Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-11","conditions":"Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":15},{"nctId":"NCT03043872","phase":"PHASE3","title":"Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2017-03-27","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":987},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT07172412","phase":"PHASE2","title":"Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-11","conditions":"Extensive Stage Lung Small Cell Cancer","enrollment":165},{"nctId":"NCT06838208","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","status":"RECRUITING","sponsor":"Anhui Provincial Cancer Hospital","startDate":"2025-02-25","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","enrollment":56},{"nctId":"NCT06448910","phase":"PHASE2","title":"Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC, Locally Advanced Lung Carcinoma","enrollment":41},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT02788461","phase":"NA","title":"Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-05","conditions":"Non-Small Cell Lung Cancer","enrollment":78},{"nctId":"NCT07155122","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09-01","conditions":"Small-Cell Carcinoma of the Esophageal","enrollment":15},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT05796089","phase":"PHASE2","title":"Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2022-01-01","conditions":"Extensive-Stage Small-Cell Lung Cancer","enrollment":35},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT04047862","phase":"PHASE1","title":"Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-08-15","conditions":"Locally Advanced and Metastatic Solid Tumors","enrollment":446},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT07109401","phase":"PHASE2","title":"Perioperative Immunotherapy for Resectable Limited-Stage SCLC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-03-01","conditions":"Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT07103408","phase":"PHASE2","title":"A Study Evaluating Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade for Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-10-01","conditions":"Small-Cell Lung Cancer (SCLC)","enrollment":56},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT07091305","phase":"PHASE2","title":"A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2025-07-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC), Chemoradiotherapy, Induction Therapy","enrollment":28},{"nctId":"NCT07083375","phase":"PHASE2","title":"A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhijie Wang","startDate":"2025-08-01","conditions":"Extensive Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT04268121","phase":"PHASE2","title":"Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2021-01-05","conditions":"Neuroendocrine Carcinoma, Digestive Cancer","enrollment":78},{"nctId":"NCT04924101","phase":"PHASE2","title":"Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-15","conditions":"Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT07061535","phase":"PHASE2","title":"Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-08-01","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer","enrollment":40},{"nctId":"NCT05224141","phase":"PHASE3","title":"Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-24","conditions":"Small Cell Lung Carcinoma","enrollment":460},{"nctId":"NCT03567642","phase":"PHASE1","title":"A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-12","conditions":"Lung Cancer","enrollment":11},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT06311968","phase":"PHASE2","title":"The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-05-06","conditions":"Thymus Epithelial Tumor, Proton Radiotherapy, Radiation Toxicity","enrollment":55},{"nctId":"NCT06186726","phase":"PHASE2","title":"Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-01-26","conditions":"Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy","enrollment":48},{"nctId":"NCT07015892","phase":"PHASE3","title":"Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Instituto de Investigación Biomédica de Salamanca","startDate":"2025-09-01","conditions":"Small Cell Lung Carcinoma","enrollment":300},{"nctId":"NCT00470223","phase":"PHASE3","title":"Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2007-03","conditions":"Sarcoma","enrollment":318},{"nctId":"NCT07008716","phase":"PHASE3","title":"Omitting CTV for Primary Tumor in LS-SCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-06-03","conditions":"SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect","enrollment":852},{"nctId":"NCT04774380","phase":"PHASE3","title":"Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-11","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":152},{"nctId":"NCT06978153","phase":"PHASE2","title":"This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-05-20","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT06931145","phase":"PHASE4","title":"Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04-15","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":50},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT05384015","phase":"PHASE2","title":"Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fundación GECP","startDate":"2022-11-07","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":46},{"nctId":"NCT06911606","phase":"PHASE2","title":"Study of Serplulimab Plus Chemotherapy as Neoadjuvant Therapy for Limited-stage Small Cell Lung Cancer (LS-SCLC)","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2024-05-22","conditions":"SCLC, Limited Stage","enrollment":45},{"nctId":"NCT06717243","phase":"","title":"Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)","status":"RECRUITING","sponsor":"Oncology Center of Biochemical Education And Research","startDate":"2025-02-20","conditions":"Small Cell Lung Cancer, Large Cell Neuroendocrine (NE) Tumors, Treatment Failure","enrollment":111},{"nctId":"NCT06851819","phase":"PHASE2","title":"Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-03-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":64},{"nctId":"NCT04005716","phase":"PHASE3","title":"Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2019-07-22","conditions":"Small Cell Lung Cancer","enrollment":457},{"nctId":"NCT06810895","phase":"","title":"Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix","status":"ENROLLING_BY_INVITATION","sponsor":"Ding Ma","startDate":"2025-02-01","conditions":"Cervix Cancer, Cadonilimab, Small Cell Neuroendocrine Carcinoma of the Cervix","enrollment":20},{"nctId":"NCT00104676","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2003-11-26","conditions":"Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor","enrollment":263},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT06784206","phase":"PHASE2","title":"Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02","conditions":"Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy","enrollment":30},{"nctId":"NCT04012606","phase":"PHASE3","title":"Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2019-07-23","conditions":"Small Cell Lung Cancer","enrollment":442},{"nctId":"NCT03509012","phase":"PHASE1","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-02","conditions":"Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":105},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT00554788","phase":"PHASE3","title":"Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-05-06","conditions":"Extraocular Retinoblastoma","enrollment":60},{"nctId":"NCT06768307","phase":"PHASE2","title":"Assessment of Adebelizumab Combined with Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-02","conditions":"SCLC, Extensive Stage, Immunotherapy, Chemotherapy","enrollment":60},{"nctId":"NCT06764368","phase":"PHASE2","title":"Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2025-01-01","conditions":"Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT04712903","phase":"PHASE3","title":"Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-16","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":101},{"nctId":"NCT06732258","phase":"PHASE1","title":"Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC","status":"NOT_YET_RECRUITING","sponsor":"Sichuan University","startDate":"2025-01-10","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":12},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT04952597","phase":"PHASE2","title":"Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2021-07-15","conditions":"Limited Stage Small Cell Lung Cancer","enrollment":126},{"nctId":"NCT03432598","phase":"PHASE2","title":"Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer","status":"COMPLETED","sponsor":"BeiGene","startDate":"2017-08-24","conditions":"Locally Advanced Lung Cancer; Metastatic Lung Cancer","enrollment":54},{"nctId":"NCT06649448","phase":"NA","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-10-10","conditions":"Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF","enrollment":200},{"nctId":"NCT03850067","phase":"PHASE1","title":"A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-03-12","conditions":"Small Cell Lung Carcinoma","enrollment":90},{"nctId":"NCT04838652","phase":"PHASE2","title":"Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2024-03-05","conditions":"Classical Hodgkin Lymphoma","enrollment":29},{"nctId":"NCT00791154","phase":"PHASE1, PHASE2","title":"QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer","status":"TERMINATED","sponsor":"NantCell, Inc.","startDate":"2008-12-02","conditions":"Lung Cancer, Small Cell Lung Cancer, Solid Tumors","enrollment":213},{"nctId":"NCT06554535","phase":"PHASE2","title":"Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2024-10-01","conditions":"Extensive-Stage Small Cell Lung Cancer, Treatment-naïve for Systemic Therapy Targeting Extensive-Stage Small Cell Lung Cancer, ECOG Performance Status Score of 0 or 1","enrollment":43},{"nctId":"NCT06536868","phase":"PHASE2","title":"Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC","status":"RECRUITING","sponsor":"Second Hospital of Shanxi Medical University","startDate":"2024-08-01","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":40},{"nctId":"NCT03723941","phase":"PHASE3","title":"Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2018-07-20","conditions":"Adrenocortical Carcinoma","enrollment":40},{"nctId":"NCT06295926","phase":"PHASE2","title":"Serplulimab Combined With CCRT for LS-SCLC.","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-04-04","conditions":"Small Cell Lung Cancer","enrollment":96},{"nctId":"NCT03641547","phase":"PHASE1","title":"M6620 Plus Standard Treatment in Oesophageal and Other Cancer","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2018-12-04","conditions":"Oesophageal Adenocarcinoma, Squamous Cell Carcinoma, Solid Tumor","enrollment":36},{"nctId":"NCT06485544","phase":"PHASE2","title":"Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-07-01","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":104},{"nctId":"NCT04562337","phase":"PHASE2","title":"SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2020-10-01","conditions":"Extensive-stage Small Cell Lung Cancer","enrollment":67},{"nctId":"NCT06477523","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-16","conditions":"SCLC, Extensive Stage","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Etoposide-Cisplatin combined chemotherapy","genericName":"Etoposide-Cisplatin combined chemotherapy","companyName":"Sumitomo Pharma (Suzhou) Co., Ltd.","companyId":"sumitomo-pharma-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etoposide and cisplatin work together as a combination chemotherapy regimen that kills cancer cells by damaging DNA through different mechanisms. Used for Small cell lung cancer, Other solid tumors (specific indications in Phase 3 trial unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}